BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Köberle V, Kronenberger B, Pleli T, Trojan J, Imelmann E, Peveling-oberhag J, Welker M, Elhendawy M, Zeuzem S, Piiper A, Waidmann O. Serum microRNA-1 and microRNA-122 are prognostic markers in patients with hepatocellular carcinoma. European Journal of Cancer 2013;49:3442-9. [DOI: 10.1016/j.ejca.2013.06.002] [Cited by in Crossref: 127] [Cited by in F6Publishing: 112] [Article Influence: 14.1] [Reference Citation Analysis]
Number Citing Articles
1 Nakao K, Miyaaki H, Ichikawa T. Antitumor function of microRNA-122 against hepatocellular carcinoma. J Gastroenterol. 2014;49:589-593. [PMID: 24531873 DOI: 10.1007/s00535-014-0932-4] [Cited by in Crossref: 73] [Cited by in F6Publishing: 76] [Article Influence: 9.1] [Reference Citation Analysis]
2 Mei H, Lin Z, Tong Q. The roles of microRNAs in neuroblastoma. World J Pediatr 2014;10:10-6. [DOI: 10.1007/s12519-014-0448-2] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 3.1] [Reference Citation Analysis]
3 Li C, Wu X, Zhang H, Yang G, Hao M, Sheng S, Sun Y, Long J, Hu C, Sun X, Li L, Zheng J. A Huaier polysaccharide reduced metastasis of human hepatocellular carcinoma SMMC-7721 cells via modulating AUF-1 signaling pathway. Tumour Biol 2015;36:6285-93. [PMID: 25787750 DOI: 10.1007/s13277-015-3314-5] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
4 Jin BX, Zhang YH, Jin WJ, Sun XY, Qiao GF, Wei YY, Sun LB, Zhang WH, Li N. MicroRNA panels as disease biomarkers distinguishing hepatitis B virus infection caused hepatitis and liver cirrhosis. Sci Rep. 2015;5:15026. [PMID: 26456479 DOI: 10.1038/srep15026] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 3.3] [Reference Citation Analysis]
5 Köberle V, Pleli T, Schmithals C, Augusto Alonso E, Haupenthal J, Bönig H, Peveling-Oberhag J, Biondi RM, Zeuzem S, Kronenberger B, Waidmann O, Piiper A. Differential stability of cell-free circulating microRNAs: implications for their utilization as biomarkers. PLoS One 2013;8:e75184. [PMID: 24073250 DOI: 10.1371/journal.pone.0075184] [Cited by in Crossref: 119] [Cited by in F6Publishing: 115] [Article Influence: 13.2] [Reference Citation Analysis]
6 Yin H, Peng X, Ren P, Cheng B, Li S, Qin C. MicroRNAs as a novel class of diagnostic biomarkers in detection of hepatocellular carcinoma: a meta-analysis. Tumour Biol 2014;35:12317-26. [PMID: 25204672 DOI: 10.1007/s13277-014-2544-2] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
7 Marceca GP, Nigita G, Calore F, Croce CM. MicroRNAs in Skeletal Muscle and Hints on Their Potential Role in Muscle Wasting During Cancer Cachexia. Front Oncol 2020;10:607196. [PMID: 33330108 DOI: 10.3389/fonc.2020.607196] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
8 Della Peruta M, Badar A, Rosales C, Chokshi S, Kia A, Nathwani D, Galante E, Yan R, Arstad E, Davidoff AM. Preferential targeting of disseminated liver tumors using a recombinant adeno-associated viral vector. Hum Gene Ther. 2015;26:94-103. [PMID: 25569358 DOI: 10.1089/hum.2014.052] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 3.1] [Reference Citation Analysis]
9 Liese J, Peveling-Oberhag J, Doering C, Schnitzbauer AA, Herrmann E, Zangos S, Hansmann ML, Moench C, Welker MW, Zeuzem S, Bechstein WO, Ulrich F. A possible role of microRNAs as predictive markers for the recurrence of hepatocellular carcinoma after liver transplantation. Transpl Int. 2016;29:369-380. [PMID: 26697811 DOI: 10.1111/tri.12733] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 3.3] [Reference Citation Analysis]
10 Jansen C, Reiberger T, Huang J, Eischeid H, Schierwagen R, Mandorfer M, Anadol E, Schwabl P, Schwarze-Zander C, Warnecke-Eberz U, Strassburg CP, Rockstroh JK, Peck-Radosavljevic M, Odenthal M, Trebicka J. Circulating miRNA-122 levels are associated with hepatic necroinflammation and portal hypertension in HIV/HCV coinfection. PLoS One 2015;10:e0116768. [PMID: 25646812 DOI: 10.1371/journal.pone.0116768] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 2.6] [Reference Citation Analysis]
11 Gupta M, Akhtar J, Sarwat M. MicroRNAs: Regulators of immunological reactions in hepatocellular carcinoma. Semin Cell Dev Biol 2021:S1084-9521(21)00134-8. [PMID: 34049801 DOI: 10.1016/j.semcdb.2021.05.025] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
12 Gibriel AA, Al-anany AM, Al-arab MAE, Azzazy HME. Investigating circulatory microRNA expression profiles in Egyptian patients infected with hepatitis C virus mediated hepatic disorders. Meta Gene 2020;26:100792. [DOI: 10.1016/j.mgene.2020.100792] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
13 Ghosh A, Ghosh A, Datta S, Dasgupta D, Das S, Ray S, Gupta S, Datta S, Chowdhury A, Chatterjee R. Hepatic miR-126 is a potential plasma biomarker for detection of hepatitis B virus infected hepatocellular carcinoma. Int J Cancer. 2016;138:2732-2744. [PMID: 26756996 DOI: 10.1002/ijc.29999] [Cited by in Crossref: 34] [Cited by in F6Publishing: 38] [Article Influence: 5.7] [Reference Citation Analysis]
14 Elghoroury EA, Eldine HG, Kamel SA, Abdelrahman AH, Mohammed A, Kamel MM, Ibrahim MH. Evaluation of miRNA-21 and miRNA Let-7 as Prognostic Markers in Patients With Breast Cancer. Clinical Breast Cancer 2018;18:e721-6. [DOI: 10.1016/j.clbc.2017.11.022] [Cited by in Crossref: 32] [Cited by in F6Publishing: 32] [Article Influence: 8.0] [Reference Citation Analysis]
15 Zhu W, Cheng L, Li M, Zuo D, Zhang N, Zhuang H, Xie D, Zeng Q, Hutchison JA, Zhao Y. Frequency Shift Raman-Based Sensing of Serum MicroRNAs for Early Diagnosis and Discrimination of Primary Liver Cancers. Anal Chem 2018;90:10144-51. [DOI: 10.1021/acs.analchem.8b01798] [Cited by in Crossref: 23] [Cited by in F6Publishing: 16] [Article Influence: 5.8] [Reference Citation Analysis]
16 Hung CH, Hu TH, Lu SN, Kuo FY, Chen CH, Wang JH, Huang CM, Lee CM, Lin CY, Yen YH, Chiu YC. Circulating microRNAs as biomarkers for diagnosis of early hepatocellular carcinoma associated with hepatitis B virus. Int J Cancer. 2016;138:714-720. [PMID: 26264553 DOI: 10.1002/ijc.29802] [Cited by in Crossref: 47] [Cited by in F6Publishing: 49] [Article Influence: 6.7] [Reference Citation Analysis]
17 Zhang YC, Xu Z, Zhang TF, Wang YL. Circulating microRNAs as diagnostic and prognostic tools for hepatocellular carcinoma. World J Gastroenterol 2015; 21(34): 9853-9862 [PMID: 26379392 DOI: 10.3748/wjg.v21.i34.9853] [Cited by in CrossRef: 50] [Cited by in F6Publishing: 47] [Article Influence: 7.1] [Reference Citation Analysis]
18 Gu P, Liu FG, Sun XG, Chen L, Li L, Liu XS. Effect of formaldehyde on miRNA122 and its downstream molecules a disintegrin and metalloproteinase 10 and serum response factor in the liver of mice. Shijie Huaren Xiaohua Zazhi 2015; 23(34): 5435-5442 [DOI: 10.11569/wcjd.v23.i34.5435] [Reference Citation Analysis]
19 Dai M, Li L, Qin X. Clinical value of miRNA-122 in the diagnosis and prognosis of various types of cancer. Oncol Lett 2019;17:3919-29. [PMID: 30881509 DOI: 10.3892/ol.2019.10024] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
20 Sun R, Xu Y, Zhang H, Yang Q, Wang K, Shi Y, Wang Z. Mechanistic Modeling of Gene Regulation and Metabolism Identifies Potential Targets for Hepatocellular Carcinoma. Front Genet 2020;11:595242. [PMID: 33424926 DOI: 10.3389/fgene.2020.595242] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
21 Vychytilova-Faltejskova P, Slaby O. Circulating Blood-Borne microRNAs as Biomarkers in Solid Tumors. Exp Suppl 2015;106:75-122. [PMID: 26608200 DOI: 10.1007/978-3-0348-0955-9_4] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
22 Salvoza NC, Klinzing DC, Gopez-Cervantes J, Baclig MO. Association of Circulating Serum miR-34a and miR-122 with Dyslipidemia among Patients with Non-Alcoholic Fatty Liver Disease. PLoS One. 2016;11:e0153497. [PMID: 27077736 DOI: 10.1371/journal.pone.0153497] [Cited by in Crossref: 65] [Cited by in F6Publishing: 66] [Article Influence: 10.8] [Reference Citation Analysis]
23 Awan FM, Naz A, Obaid A, Ali A, Ahmad J, Anjum S, Janjua HA. Identification of Circulating Biomarker Candidates for Hepatocellular Carcinoma (HCC): An Integrated Prioritization Approach. PLoS One 2015;10:e0138913. [PMID: 26414287 DOI: 10.1371/journal.pone.0138913] [Cited by in Crossref: 22] [Cited by in F6Publishing: 26] [Article Influence: 3.1] [Reference Citation Analysis]
24 Singh AK, Rooge SB, Varshney A, Vasudevan M, Bhardwaj A, Venugopal SK, Trehanpati N, Kumar M, Geffers R, Kumar V, Sarin SK. Global microRNA expression profiling in the liver biopsies of hepatitis B virus-infected patients suggests specific microRNA signatures for viral persistence and hepatocellular injury. Hepatology. 2018;67:1695-1709. [PMID: 29194684 DOI: 10.1002/hep.29690] [Cited by in Crossref: 33] [Cited by in F6Publishing: 35] [Article Influence: 8.3] [Reference Citation Analysis]
25 Gambari R, Brognara E, Spandidos DA, Fabbri E. Targeting oncomiRNAs and mimicking tumor suppressor miRNAs: Νew trends in the development of miRNA therapeutic strategies in oncology (Review). Int J Oncol 2016;49:5-32. [PMID: 27175518 DOI: 10.3892/ijo.2016.3503] [Cited by in Crossref: 108] [Cited by in F6Publishing: 114] [Article Influence: 18.0] [Reference Citation Analysis]
26 Wang L, Liu M, Zhu H, Rong W, Wu F, An S, Liu F, Feng L, Wu J, Xu N. Identification of recurrence-related serum microRNAs in hepatocellular carcinoma following hepatectomy. Cancer Biol Ther. 2015;16:1445-1452. [PMID: 26176380 DOI: 10.1080/15384047.2015.1071730] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 2.9] [Reference Citation Analysis]
27 Zhang Y, Wei C, Guo CC, Bi RX, Xie J, Guan DH, Yang CH, Jiang YH. Prognostic value of microRNAs in hepatocellular carcinoma: a meta-analysis. Oncotarget 2017;8:107237-57. [PMID: 29291025 DOI: 10.18632/oncotarget.20883] [Cited by in Crossref: 13] [Cited by in F6Publishing: 17] [Article Influence: 2.6] [Reference Citation Analysis]
28 Pelizzaro F, Cardin R, Penzo B, Pinto E, Vitale A, Cillo U, Russo FP, Farinati F. Liquid Biopsy in Hepatocellular Carcinoma: Where Are We Now? Cancers (Basel) 2021;13:2274. [PMID: 34068786 DOI: 10.3390/cancers13092274] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
29 Feng R, Beeharry MK, Lu S, Sah BK, Yuan F, Yan M, Liu B, Li C, Zhu Z. Down-regulated serum miR-126 is associated with aggressive progression and poor prognosis of gastric cancer. Cancer Biomark 2018;22:119-26. [PMID: 29562500 DOI: 10.3233/CBM-171099] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
30 Liu Z, Wang Y, Borlak J, Tong W. Mechanistically linked serum miRNAs distinguish between drug induced and fatty liver disease of different grades. Sci Rep 2016;6:23709. [PMID: 27045805 DOI: 10.1038/srep23709] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 2.7] [Reference Citation Analysis]
31 Zhang H, Zhang Z, Gao L, Qiao Z, Yu M, Yu B, Yang T. miR-1-3p suppresses proliferation of hepatocellular carcinoma through targeting SOX9. Onco Targets Ther 2019;12:2149-57. [PMID: 30962696 DOI: 10.2147/OTT.S197326] [Cited by in Crossref: 17] [Cited by in F6Publishing: 8] [Article Influence: 5.7] [Reference Citation Analysis]
32 Qiu Z, Dai Y. Roadmap of miR-122-related clinical application from bench to bedside. Expert Opin Investig Drugs 2014;23:347-55. [PMID: 24354366 DOI: 10.1517/13543784.2014.867327] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 1.7] [Reference Citation Analysis]
33 Weiss M, Brandenburg LO, Burchardt M, Stope MB. MicroRNA-1 properties in cancer regulatory networks and tumor biology. Crit Rev Oncol Hematol 2016;104:71-7. [PMID: 27286699 DOI: 10.1016/j.critrevonc.2016.05.014] [Cited by in Crossref: 11] [Cited by in F6Publishing: 16] [Article Influence: 1.8] [Reference Citation Analysis]
34 Pelizzaro F, Cardin R, Sartori A, Imondi A, Penzo B, Aliberti C, Ponzoni A, Vitale A, Cillo U, Farinati F. Circulating MicroRNA-21 and MicroRNA-122 as Prognostic Biomarkers in Hepatocellular Carcinoma Patients Treated with Transarterial Chemoembolization. Biomedicines 2021;9:890. [PMID: 34440094 DOI: 10.3390/biomedicines9080890] [Reference Citation Analysis]
35 Franck M, Schütte K, Malfertheiner P, Link A. Prognostic value of serum microRNA-122 in hepatocellular carcinoma is dependent on coexisting clinical and laboratory factors. World J Gastroenterol 2020; 26(1): 86-96 [PMID: 31933516 DOI: 10.3748/wjg.v26.i1.86] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
36 Fiorino S, Bacchi-Reggiani ML, Visani M, Acquaviva G, Fornelli A, Masetti M, Tura A, Grizzi F, Zanello M, Mastrangelo L, Lombardi R, Di Tommaso L, Bondi A, Sabbatani S, Domanico A, Fabbri C, Leandri P, Pession A, Jovine E, de Biase D. MicroRNAs as possible biomarkers for diagnosis and prognosis of hepatitis B- and C-related-hepatocellular-carcinoma. World J Gastroenterol 2016; 22(15): 3907-3936 [PMID: 27099435 DOI: 10.3748/wjg.v22.i15.3907] [Cited by in CrossRef: 33] [Cited by in F6Publishing: 35] [Article Influence: 5.5] [Reference Citation Analysis]
37 Shen S, Lin Y, Yuan X, Shen L, Chen J, Chen L, Qin L, Shen B. Biomarker MicroRNAs for Diagnosis, Prognosis and Treatment of Hepatocellular Carcinoma: A Functional Survey and Comparison. Sci Rep. 2016;6:38311. [PMID: 27917899 DOI: 10.1038/srep38311] [Cited by in Crossref: 44] [Cited by in F6Publishing: 46] [Article Influence: 7.3] [Reference Citation Analysis]
38 Raitoharju E, Seppälä I, Lyytikäinen LP, Viikari J, Ala-Korpela M, Soininen P, Kangas AJ, Waldenberger M, Klopp N, Illig T, Leiviskä J, Loo BM, Oksala N, Kähönen M, Hutri-Kähönen N, Laaksonen R, Raitakari O, Lehtimäki T. Blood hsa-miR-122-5p and hsa-miR-885-5p levels associate with fatty liver and related lipoprotein metabolism-The Young Finns Study. Sci Rep 2016;6:38262. [PMID: 27917915 DOI: 10.1038/srep38262] [Cited by in Crossref: 36] [Cited by in F6Publishing: 35] [Article Influence: 6.0] [Reference Citation Analysis]
39 Karihtala P, Porvari K, Soini Y, Haapasaari KM. Redox Regulating Enzymes and Connected MicroRNA Regulators Have Prognostic Value in Classical Hodgkin Lymphomas. Oxid Med Cell Longev 2017;2017:2696071. [PMID: 28377796 DOI: 10.1155/2017/2696071] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 1.6] [Reference Citation Analysis]
40 Labgaa I, Villanueva A, Dormond O, Demartines N, Melloul E. The Role of Liquid Biopsy in Hepatocellular Carcinoma Prognostication. Cancers (Basel) 2021;13:659. [PMID: 33562173 DOI: 10.3390/cancers13040659] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
41 Chen L, Chu F, Cao Y, Shao J, Wang F. Serum miR-182 and miR-331-3p as diagnostic and prognostic markers in patients with hepatocellular carcinoma. Tumor Biol 2015;36:7439-47. [DOI: 10.1007/s13277-015-3430-2] [Cited by in Crossref: 52] [Cited by in F6Publishing: 54] [Article Influence: 7.4] [Reference Citation Analysis]
42 Zhi F, Shao N, Wang R, Deng D, Xue L, Wang Q, Zhang Y, Shi Y, Xia X, Wang S, Lan Q, Yang Y. Identification of 9 serum microRNAs as potential noninvasive biomarkers of human astrocytoma. Neuro Oncol 2015;17:383-91. [PMID: 25140035 DOI: 10.1093/neuonc/nou169] [Cited by in Crossref: 51] [Cited by in F6Publishing: 54] [Article Influence: 6.4] [Reference Citation Analysis]
43 Song PP, Xia JF, Inagaki Y, Hasegawa K, Sakamoto Y, Kokudo N, Tang W. Controversies regarding and perspectives on clinical utility of biomarkers in hepatocellular carcinoma. World J Gastroenterol 2016; 22(1): 262-274 [PMID: 26755875 DOI: 10.3748/wjg.v22.i1.262] [Cited by in CrossRef: 69] [Cited by in F6Publishing: 61] [Article Influence: 11.5] [Reference Citation Analysis]
44 Piñero F, Dirchwolf M, Pessôa MG. Biomarkers in Hepatocellular Carcinoma: Diagnosis, Prognosis and Treatment Response Assessment. Cells 2020;9:E1370. [PMID: 32492896 DOI: 10.3390/cells9061370] [Cited by in Crossref: 12] [Cited by in F6Publishing: 18] [Article Influence: 6.0] [Reference Citation Analysis]
45 Song L, Zhang W, Chang Z, Pan Y, Zong H, Fan Q, Wang L. miR-4417 Targets Tripartite Motif-Containing 35 (TRIM35) and Regulates Pyruvate Kinase Muscle 2 (PKM2) Phosphorylation to Promote Proliferation and Suppress Apoptosis in Hepatocellular Carcinoma Cells. Med Sci Monit 2017;23:1741-50. [PMID: 28394882 DOI: 10.12659/msm.900296] [Cited by in Crossref: 10] [Cited by in F6Publishing: 14] [Article Influence: 2.0] [Reference Citation Analysis]
46 Li G, Pu Y. MicroRNA signatures in total peripheral blood of gallbladder cancer patients. Tumour Biol. 2015;36:6985-6990. [PMID: 25861754 DOI: 10.1007/s13277-015-3412-4] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 3.0] [Reference Citation Analysis]
47 Rocci A, Hofmeister CC, Pichiorri F. The potential of miRNAs as biomarkers for multiple myeloma. Expert Review of Molecular Diagnostics 2014;14:947-59. [DOI: 10.1586/14737159.2014.946906] [Cited by in Crossref: 14] [Cited by in F6Publishing: 17] [Article Influence: 1.8] [Reference Citation Analysis]
48 Reyes RK, Motiwala T, Jacob ST. Regulation of glucose metabolism in hepatocarcinogenesis by microRNAs. Gene Expr. 2014;16:85-92. [PMID: 24801169 DOI: 10.3727/105221614X13919976902093] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 2.1] [Reference Citation Analysis]
49 El-abd NE, Fawzy NA, El-sheikh SM, Soliman ME. Circulating miRNA-122, miRNA-199a, and miRNA-16 as Biomarkers for Early Detection of Hepatocellular Carcinoma in Egyptian Patients with Chronic Hepatitis C Virus Infection. Mol Diagn Ther 2015;19:213-20. [DOI: 10.1007/s40291-015-0148-1] [Cited by in Crossref: 47] [Cited by in F6Publishing: 47] [Article Influence: 6.7] [Reference Citation Analysis]
50 Piluso A, Gragnani L, Fognani E, Grandini E, Monti M, Stasi C, Loggi E, Margotti M, Conti F, Andreone P, Zignego AL. Deregulation of microRNA expression in peripheral blood mononuclear cells from patients with HCV-related malignancies. Hepatol Int 2015;9:586-93. [PMID: 26272105 DOI: 10.1007/s12072-015-9658-5] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
51 Di Ieva A, Butz H, Niamah M, Rotondo F, De Rosa S, Sav A, Yousef GM, Kovacs K, Cusimano MD. MicroRNAs as biomarkers in pituitary tumors. Neurosurgery 2014;75:181-9; discussion 188-9. [PMID: 24739366 DOI: 10.1227/NEU.0000000000000369] [Cited by in Crossref: 29] [Cited by in F6Publishing: 18] [Article Influence: 3.6] [Reference Citation Analysis]
52 Fernandez-Mercado M, Manterola L, Larrea E, Goicoechea I, Arestin M, Armesto M, Otaegui D, Lawrie CH. The circulating transcriptome as a source of non-invasive cancer biomarkers: concepts and controversies of non-coding and coding RNA in body fluids. J Cell Mol Med 2015;19:2307-23. [PMID: 26119132 DOI: 10.1111/jcmm.12625] [Cited by in Crossref: 53] [Cited by in F6Publishing: 49] [Article Influence: 7.6] [Reference Citation Analysis]
53 Ning Q, Liu YF, Ye PJ, Gao P, Li ZP, Tang SY, He DX, Tang SS, Wei H, Yu CY. Delivery of Liver-Specific miRNA-122 Using a Targeted Macromolecular Prodrug toward Synergistic Therapy for Hepatocellular Carcinoma. ACS Appl Mater Interfaces 2019;11:10578-88. [PMID: 30802029 DOI: 10.1021/acsami.9b00634] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 6.0] [Reference Citation Analysis]
54 Wang SS, Wu LJ, Li JJ, Xiao HB, He Y, Yan YX. A meta-analysis of dysregulated miRNAs in coronary heart disease. Life Sci 2018;215:170-81. [PMID: 30423308 DOI: 10.1016/j.lfs.2018.11.016] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 5.0] [Reference Citation Analysis]
55 Akuta N, Kawamura Y, Arase Y, Saitoh S, Fujiyama S, Sezaki H, Hosaka T, Kobayashi M, Kobayashi M, Suzuki Y, Suzuki F, Ikeda K, Kumada H. Circulating MicroRNA-122 and Fibrosis Stage Predict Mortality of Japanese Patients With Histopathologically Confirmed NAFLD. Hepatol Commun 2020;4:66-76. [PMID: 31909356 DOI: 10.1002/hep4.1445] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
56 Ambade A, Satishchandran A, Szabo G. Alcoholic hepatitis accelerates early hepatobiliary cancer by increasing stemness and miR-122-mediated HIF-1α activation. Sci Rep 2016;6:21340. [PMID: 26888602 DOI: 10.1038/srep21340] [Cited by in Crossref: 46] [Cited by in F6Publishing: 47] [Article Influence: 7.7] [Reference Citation Analysis]
57 El-Garem H, Ammer A, Shehab H, Shaker O, Anwer M, El-Akel W, Omar H. Circulating microRNA, miR-122 and miR-221 signature in Egyptian patients with chronic hepatitis C related hepatocellular carcinoma. World J Hepatol 2014; 6(11): 818-824 [PMID: 25429320 DOI: 10.4254/wjh.v6.i11.818] [Cited by in Crossref: 44] [Cited by in F6Publishing: 43] [Article Influence: 5.5] [Reference Citation Analysis]
58 Okajima W, Komatsu S, Ichikawa D, Miyamae M, Ohashi T, Imamura T, Kiuchi J, Nishibeppu K, Arita T, Konishi H, Shiozaki A, Morimura R, Ikoma H, Okamoto K, Otsuji E. Liquid biopsy in patients with hepatocellular carcinoma: Circulating tumor cells and cell-free nucleic acids. World J Gastroenterol 2017; 23(31): 5650-5668 [PMID: 28883691 DOI: 10.3748/wjg.v23.i31.5650] [Cited by in CrossRef: 44] [Cited by in F6Publishing: 43] [Article Influence: 8.8] [Reference Citation Analysis]
59 Chao A, Lai CH, Chen HC, Lin CY, Tsai CL, Tang YH, Huang HJ, Lin CT, Chen MY, Huang KG, Chou HH, Chang TC, Chen SJ, Wang TH. Serum microRNAs in clear cell carcinoma of the ovary. Taiwan J Obstet Gynecol 2014;53:536-41. [PMID: 25510697 DOI: 10.1016/j.tjog.2014.07.005] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 2.7] [Reference Citation Analysis]
60 Shehab-Eldeen S, Nada A, Abou-Elela D, El-Naidany S, Arafat E, Omar T. Diagnostic Performance of microRNA-122 and microRNA-224 in Hepatitis C Virus-Induced Hepatocellular Carcinoma (HCC). Asian Pac J Cancer Prev 2019;20:2515-22. [PMID: 31450927 DOI: 10.31557/APJCP.2019.20.8.2515] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
61 Cheng G. Circulating miRNAs: roles in cancer diagnosis, prognosis and therapy. Adv Drug Deliv Rev. 2015;81:75-93. [PMID: 25220354 DOI: 10.1016/j.addr.2014.09.001] [Cited by in Crossref: 193] [Cited by in F6Publishing: 192] [Article Influence: 24.1] [Reference Citation Analysis]
62 Siracusa J, Koulmann N, Banzet S. Circulating myomiRs: a new class of biomarkers to monitor skeletal muscle in physiology and medicine. J Cachexia Sarcopenia Muscle 2018;9:20-7. [PMID: 29193905 DOI: 10.1002/jcsm.12227] [Cited by in Crossref: 51] [Cited by in F6Publishing: 51] [Article Influence: 10.2] [Reference Citation Analysis]
63 Wang TH, Lin YS, Chen Y, Yeh CT, Huang YL, Hsieh TH, Shieh TM, Hsueh C, Chen TC. Long non-coding RNA AOC4P suppresses hepatocellular carcinoma metastasis by enhancing vimentin degradation and inhibiting epithelial-mesenchymal transition. Oncotarget. 2015;6:23342-23357. [PMID: 26160837 DOI: 10.18632/oncotarget.4344] [Cited by in Crossref: 65] [Cited by in F6Publishing: 80] [Article Influence: 10.8] [Reference Citation Analysis]
64 Benz F, Roy S, Trautwein C, Roderburg C, Luedde T. Circulating MicroRNAs as Biomarkers for Sepsis. Int J Mol Sci 2016;17:E78. [PMID: 26761003 DOI: 10.3390/ijms17010078] [Cited by in Crossref: 104] [Cited by in F6Publishing: 108] [Article Influence: 17.3] [Reference Citation Analysis]
65 Guo R, Fan G, Zhang J, Wu C, Du Y, Ye H, Li Z, Wang L, Zhang Z, Zhang L, Zhao Y, Lu Z. A 9-microRNA Signature in Serum Serves as a Noninvasive Biomarker in Early Diagnosis of Alzheimer’s Disease. JAD 2017;60:1365-77. [DOI: 10.3233/jad-170343] [Cited by in Crossref: 43] [Cited by in F6Publishing: 30] [Article Influence: 8.6] [Reference Citation Analysis]
66 Singh R, Ramasubramanian B, Kanji S, Chakraborty AR, Haque SJ, Chakravarti A. Circulating microRNAs in cancer: Hope or hype? Cancer Lett 2016;381:113-21. [PMID: 27471105 DOI: 10.1016/j.canlet.2016.07.002] [Cited by in Crossref: 48] [Cited by in F6Publishing: 44] [Article Influence: 8.0] [Reference Citation Analysis]
67 Chakraborty C, Das S. Profiling cell-free and circulating miRNA: a clinical diagnostic tool for different cancers. Tumour Biol. 2016;37:5705-5714. [PMID: 26831657 DOI: 10.1007/s13277-016-4907-3] [Cited by in Crossref: 43] [Cited by in F6Publishing: 40] [Article Influence: 7.2] [Reference Citation Analysis]
68 Bronte F, Bronte G, Fanale D, Caruso S, Bronte E, Bavetta MG, Fiorentino E, Rolfo C, Bazan V, Di Marco V, Russo A. HepatomiRNoma: The proposal of a new network of targets for diagnosis, prognosis and therapy in hepatocellular carcinoma. Crit Rev Oncol Hematol 2016;97:312-21. [PMID: 26603462 DOI: 10.1016/j.critrevonc.2015.09.007] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 3.0] [Reference Citation Analysis]
69 Xu Y, Bu X, Dai C, Shang C. High serum microRNA-122 level is independently associated with higher overall survival rate in hepatocellular carcinoma patients. Tumour Biol. 2015;36:4773-4776. [PMID: 25636448 DOI: 10.1007/s13277-015-3128-5] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 3.6] [Reference Citation Analysis]
70 Li L, Diao W, Zen K. Micro-ribonucleic acids: potential noninvasive biomarkers for hepatocellular carcinoma. J Hepatocell Carcinoma 2014;1:21-33. [PMID: 27508173 DOI: 10.2147/JHC.S44463] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
71 Qiu G, Zhang XB, Zhang SQ, Liu PL, Wu W, Zhang JY, Dai SR. Dysregulation of MALAT1 and miR-619-5p as a prognostic indicator in advanced colorectal carcinoma. Oncol Lett 2016;12:5036-42. [PMID: 28101234 DOI: 10.3892/ol.2016.5312] [Cited by in Crossref: 16] [Cited by in F6Publishing: 19] [Article Influence: 2.7] [Reference Citation Analysis]
72 Mizuguchi Y, Takizawa T, Yoshida H, Uchida E. Dysregulated miRNA in progression of hepatocellular carcinoma: A systematic review. Hepatol Res. 2016;46:391-406. [PMID: 26490438 DOI: 10.1111/hepr.12606] [Cited by in Crossref: 65] [Cited by in F6Publishing: 67] [Article Influence: 9.3] [Reference Citation Analysis]
73 Cho HJ, Kim JK, Nam JS, Wang HJ, Lee JH, Kim BW, Kim SS, Noh CK, Shin SJ, Lee KM, Cho SW, Cheong JY. High circulating microRNA-122 expression is a poor prognostic marker in patients with hepatitis B virus-related hepatocellular carcinoma who undergo radiofrequency ablation. Clinical Biochemistry 2015;48:1073-8. [DOI: 10.1016/j.clinbiochem.2015.06.019] [Cited by in Crossref: 34] [Cited by in F6Publishing: 34] [Article Influence: 4.9] [Reference Citation Analysis]
74 Rodríguez M, Silva J, López-Alfonso A, López-Muñiz MB, Peña C, Domínguez G, García JM, López-Gónzalez A, Méndez M, Provencio M, García V, Bonilla F. Different exosome cargo from plasma/bronchoalveolar lavage in non-small-cell lung cancer. Genes Chromosomes Cancer 2014;53:713-24. [PMID: 24764226 DOI: 10.1002/gcc.22181] [Cited by in Crossref: 35] [Cited by in F6Publishing: 66] [Article Influence: 4.4] [Reference Citation Analysis]
75 Klingenberg M, Matsuda A, Diederichs S, Patel T. Non-coding RNA in hepatocellular carcinoma: Mechanisms, biomarkers and therapeutic targets. J Hepatol. 2017;67:603-618. [PMID: 28438689 DOI: 10.1016/j.jhep.2017.04.009] [Cited by in Crossref: 178] [Cited by in F6Publishing: 186] [Article Influence: 35.6] [Reference Citation Analysis]
76 Li F, Ma N, Zhao R, Wu G, Zhang Y, Qiao Y, Han D, Xu Y, Xiang Y, Yan B, Jin J, Lv G, Wang L, Xu C, Gao X, Luo S. Overexpression of miR-483-5p/3p cooperate to inhibit mouse liver fibrosis by suppressing the TGF-β stimulated HSCs in transgenic mice. J Cell Mol Med 2014;18:966-74. [PMID: 24801603 DOI: 10.1111/jcmm.12293] [Cited by in Crossref: 33] [Cited by in F6Publishing: 32] [Article Influence: 4.1] [Reference Citation Analysis]
77 Weis A, Marquart L, Calvopina DA, Genz B, Ramm GA, Skoien R. Serum MicroRNAs as Biomarkers in Hepatitis C: Preliminary Evidence of a MicroRNA Panel for the Diagnosis of Hepatocellular Carcinoma. Int J Mol Sci. 2019;20. [PMID: 30781550 DOI: 10.3390/ijms20040864] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 5.3] [Reference Citation Analysis]
78 Kawaguchi T, Komatsu S, Ichikawa D, Tsujiura M, Takeshita H, Hirajima S, Miyamae M, Okajima W, Ohashi T, Imamura T. Circulating MicroRNAs: A Next-Generation Clinical Biomarker for Digestive System Cancers. Int J Mol Sci. 2016;17. [PMID: 27598137 DOI: 10.3390/ijms17091459] [Cited by in Crossref: 44] [Cited by in F6Publishing: 40] [Article Influence: 7.3] [Reference Citation Analysis]
79 Liu FY, Zhou SJ, Deng YL, Zhang ZY, Zhang EL, Wu ZB, Huang ZY, Chen XP. MiR-216b is involved in pathogenesis and progression of hepatocellular carcinoma through HBx-miR-216b-IGF2BP2 signaling pathway. Cell Death Dis. 2015;6:e1670. [PMID: 25741595 DOI: 10.1038/cddis.2015.46] [Cited by in Crossref: 67] [Cited by in F6Publishing: 76] [Article Influence: 9.6] [Reference Citation Analysis]
80 Tan YL, Bai ZG, Zou WL, Ma XM, Wang TT, Guo W, Liu J, Li JS, Jie-Yin, Zang YJ, Zhang ZT. miR-744 is a potential prognostic marker in patients with hepatocellular carcinoma. Clin Res Hepatol Gastroenterol 2015;39:359-65. [PMID: 25543521 DOI: 10.1016/j.clinre.2014.09.010] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 2.8] [Reference Citation Analysis]
81 Demerdash HM, Hussien HM, Hassouna E, Arida EA. Detection of MicroRNA in Hepatic Cirrhosis and Hepatocellular Carcinoma in Hepatitis C Genotype-4 in Egyptian Patients. Biomed Res Int 2017;2017:1806069. [PMID: 28642869 DOI: 10.1155/2017/1806069] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 2.2] [Reference Citation Analysis]
82 Hao M, Zang M, Wendlandt E, Xu Y, An G, Gong D, Li F, Qi F, Zhang Y, Yang Y, Zhan F, Qiu L. Low serum miR-19a expression as a novel poor prognostic indicator in multiple myeloma. Int J Cancer 2015;136:1835-44. [PMID: 25220540 DOI: 10.1002/ijc.29199] [Cited by in Crossref: 43] [Cited by in F6Publishing: 43] [Article Influence: 5.4] [Reference Citation Analysis]
83 Belli R, Ferraro E, Molfino A, Carletti R, Tambaro F, Costelli P, Muscaritoli M. Liquid Biopsy for Cancer Cachexia: Focus on Muscle-Derived microRNAs. Int J Mol Sci 2021;22:9007. [PMID: 34445710 DOI: 10.3390/ijms22169007] [Reference Citation Analysis]
84 Schütte K, Schulz C, Link A, Malfertheiner P. Current biomarkers for hepatocellular carcinoma: Surveillance, diagnosis and prediction of prognosis. World J Hepatol 2015; 7(2): 139-149 [PMID: 25729470 DOI: 10.4254/wjh.v7.i2.139] [Cited by in Crossref: 43] [Cited by in F6Publishing: 48] [Article Influence: 6.1] [Reference Citation Analysis]
85 Enache LS, Enache EL, Ramière C, Diaz O, Bancu L, Sin A, André P. Circulating RNA molecules as biomarkers in liver disease. Int J Mol Sci 2014;15:17644-66. [PMID: 25272224 DOI: 10.3390/ijms151017644] [Cited by in Crossref: 37] [Cited by in F6Publishing: 33] [Article Influence: 4.6] [Reference Citation Analysis]
86 Nasr MA, Salah RA, Abd Elkodous M, Elshenawy SE, El-Badri N. Dysregulated MicroRNA Fingerprints and Methylation Patterns in Hepatocellular Carcinoma, Cancer Stem Cells, and Mesenchymal Stem Cells. Front Cell Dev Biol 2019;7:229. [PMID: 31681762 DOI: 10.3389/fcell.2019.00229] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.7] [Reference Citation Analysis]
87 Fleischhacker M, Schmidt B. Extracellular Nucleic Acids and Cancer. In: Gahan PB, editor. Circulating Nucleic Acids in Early Diagnosis, Prognosis and Treatment Monitoring. Dordrecht: Springer Netherlands; 2015. pp. 239-93. [DOI: 10.1007/978-94-017-9168-7_10] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
88 Niederwieser C, Kohlschmidt J, Volinia S, Whitman SP, Metzeler KH, Eisfeld AK, Maharry K, Yan P, Frankhouser D, Becker H, Schwind S, Carroll AJ, Nicolet D, Mendler JH, Curfman JP, Wu YZ, Baer MR, Powell BL, Kolitz JE, Moore JO, Carter TH, Bundschuh R, Larson RA, Stone RM, Mrózek K, Marcucci G, Bloomfield CD. Prognostic and biologic significance of DNMT3B expression in older patients with cytogenetically normal primary acute myeloid leukemia. Leukemia 2015;29:567-75. [PMID: 25204569 DOI: 10.1038/leu.2014.267] [Cited by in Crossref: 46] [Cited by in F6Publishing: 48] [Article Influence: 5.8] [Reference Citation Analysis]
89 Zhao C, Li Y, Zhang M, Yang Y, Chang L. miR-126 inhibits cell proliferation and induces cell apoptosis of hepatocellular carcinoma cells partially by targeting Sox2. Hum Cell. 2015;28:91-99. [PMID: 25585946 DOI: 10.1007/s13577-014-0105-z] [Cited by in Crossref: 41] [Cited by in F6Publishing: 35] [Article Influence: 5.9] [Reference Citation Analysis]
90 Falcon-perez JM, Royo F. Circulating RNA: looking at the liver through a frosted glass. Biomarkers 2015;20:339-54. [DOI: 10.3109/1354750x.2015.1101785] [Cited by in Crossref: 7] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
91 El-Diwany R, Wasilewski LN, Witwer KW, Bailey JR, Page K, Ray SC, Cox AL, Thomas DL, Balagopal A. Acute Hepatitis C Virus Infection Induces Consistent Changes in Circulating MicroRNAs That Are Associated with Nonlytic Hepatocyte Release. J Virol 2015;89:9454-64. [PMID: 26157120 DOI: 10.1128/JVI.00955-15] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 1.9] [Reference Citation Analysis]
92 Yu F, Lu Z, Chen B, Dong P, Zheng J. microRNA-150: a promising novel biomarker for hepatitis B virus-related hepatocellular carcinoma. Diagn Pathol 2015;10:129. [PMID: 26215970 DOI: 10.1186/s13000-015-0369-y] [Cited by in Crossref: 34] [Cited by in F6Publishing: 29] [Article Influence: 4.9] [Reference Citation Analysis]
93 Nogales-Gadea G, Ramos-Fransi A, Suárez-Calvet X, Navas M, Rojas-García R, Mosquera JL, Díaz-Manera J, Querol L, Gallardo E, Illa I. Analysis of serum miRNA profiles of myasthenia gravis patients. PLoS One 2014;9:e91927. [PMID: 24637658 DOI: 10.1371/journal.pone.0091927] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 3.3] [Reference Citation Analysis]
94 Gong J, He XX, Tian A. Emerging role of microRNA in hepatocellular carcinoma (Review). Oncol Lett 2015;9:1027-33. [PMID: 25663852 DOI: 10.3892/ol.2014.2816] [Cited by in Crossref: 34] [Cited by in F6Publishing: 32] [Article Influence: 4.3] [Reference Citation Analysis]
95 Wang TH, Yu CC, Lin YS, Chen TC, Yeh CT, Liang KH, Shieh TM, Chen CY, Hsueh C. Long noncoding RNA CPS1-IT1 suppresses the metastasis of hepatocellular carcinoma by regulating HIF-1α activity and inhibiting epithelial-mesenchymal transition. Oncotarget 2016;7:43588-603. [PMID: 27248828 DOI: 10.18632/oncotarget.9635] [Cited by in Crossref: 33] [Cited by in F6Publishing: 44] [Article Influence: 6.6] [Reference Citation Analysis]
96 Ghidini M, Braconi C. Non-Coding RNAs in Primary Liver Cancer. Front Med (Lausanne). 2015;2:36. [PMID: 26131450 DOI: 10.3389/fmed.2015.00036] [Cited by in Crossref: 15] [Cited by in F6Publishing: 21] [Article Influence: 2.1] [Reference Citation Analysis]
97 Wang Y, Tian Y. miRNA for diagnosis and clinical implications of human hepatocellular carcinoma. Hepatol Res 2016;46:89-99. [PMID: 26284466 DOI: 10.1111/hepr.12571] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 2.3] [Reference Citation Analysis]
98 Schwarzenbach H, Nishida N, Calin GA, Pantel K. Clinical relevance of circulating cell-free microRNAs in cancer. Nat Rev Clin Oncol. 2014;11:145-156. [PMID: 24492836 DOI: 10.1038/nrclinonc.2014.5] [Cited by in Crossref: 621] [Cited by in F6Publishing: 612] [Article Influence: 77.6] [Reference Citation Analysis]
99 Maravelia P, Silva DN, Rovesti G, Chrobok M, Stål P, Lu YC, Pasetto A. Liquid Biopsy in Hepatocellular Carcinoma: Opportunities and Challenges for Immunotherapy. Cancers (Basel) 2021;13:4334. [PMID: 34503144 DOI: 10.3390/cancers13174334] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
100 Suehiro T, Miyaaki H, Kanda Y, Shibata H, Honda T, Ozawa E, Miuma S, Taura N, Nakao K. Serum exosomal microRNA-122 and microRNA-21 as predictive biomarkers in transarterial chemoembolization-treated hepatocellular carcinoma patients. Oncol Lett. 2018;16:3267-3273. [PMID: 30127924 DOI: 10.3892/ol.2018.8991] [Cited by in Crossref: 10] [Cited by in F6Publishing: 15] [Article Influence: 2.5] [Reference Citation Analysis]
101 Li G, Shen Q, Li C, Li D, Chen J, He M. Identification of circulating MicroRNAs as novel potential biomarkers for hepatocellular carcinoma detection: a systematic review and meta-analysis. Clin Transl Oncol 2015;17:684-93. [PMID: 25956842 DOI: 10.1007/s12094-015-1294-y] [Cited by in Crossref: 30] [Cited by in F6Publishing: 27] [Article Influence: 4.3] [Reference Citation Analysis]
102 Li Z, Liu R, Lv Y. ICPMS based multiplexed bioassay: Principles, approaches and progresses. Applied Spectroscopy Reviews. [DOI: 10.1080/05704928.2021.1918703] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
103 Hsu A, Chen SJ, Chang YS, Chen HC, Chu PH. Systemic approach to identify serum microRNAs as potential biomarkers for acute myocardial infarction. Biomed Res Int. 2014;2014:418628. [PMID: 24900964 DOI: 10.1155/2014/418628] [Cited by in Crossref: 42] [Cited by in F6Publishing: 50] [Article Influence: 5.3] [Reference Citation Analysis]
104 Maierthaler M, Benner A, Hoffmeister M, Surowy H, Jansen L, Knebel P, Chang-Claude J, Brenner H, Burwinkel B. Plasma miR-122 and miR-200 family are prognostic markers in colorectal cancer. Int J Cancer. 2017;140:176-187. [PMID: 27632639 DOI: 10.1002/ijc.30433] [Cited by in Crossref: 55] [Cited by in F6Publishing: 61] [Article Influence: 9.2] [Reference Citation Analysis]
105 Barrera-Saldaña HA, Fernández-Garza LE, Barrera-Barrera SA. Liquid biopsy in chronic liver disease. Ann Hepatol 2021;20:100197. [PMID: 32444248 DOI: 10.1016/j.aohep.2020.03.008] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
106 Ziogas IA, Sioutas G, Mylonas KS, Tsoulfas G. Role of MicroRNA in the Diagnosis and Management of Hepatocellular Carcinoma. Microrna 2020;9:25-40. [PMID: 31218966 DOI: 10.2174/2211536608666190619155406] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
107 Song HF, Xu P. New serological markers for liver damage. Shijie Huaren Xiaohua Zazhi 2017; 25(30): 2681-2688 [DOI: 10.11569/wcjd.v25.i30.2681] [Reference Citation Analysis]
108 Donzelli S, Farneti A, Marucci L, Ganci F, Sacconi A, Strano S, Sanguineti G, Blandino G. Non-coding RNAs as Putative Biomarkers of Cancer-Associated Cachexia. Front Cell Dev Biol 2020;8:257. [PMID: 32373612 DOI: 10.3389/fcell.2020.00257] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
109 Huang X, Gong S, Ma Y, Cai X, Zhou L, Luo Y, Li M, Liu W, Zhang S, Zhang X, Ren Q, Zhu Y, Zhou X, Zhang R, Chen L, Gao X, Zhang F, Wang Y, Han X, Ji L. Lower Circulating miR-122 Level in Patients with HNF1A Variant-Induced Diabetes Compared with Type 2 Diabetes. J Diabetes Res 2018;2018:7842064. [PMID: 30155490 DOI: 10.1155/2018/7842064] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
110 Wahb AMSE, El Kassas M, Khamis AK, Elhelbawy M, Elhelbawy N, Habieb MSE. Circulating microRNA 9-3p and serum endocan as potential biomarkers for hepatitis C virus-related hepatocellular carcinoma. World J Hepatol 2021; 13(11): 1753-1765 [PMID: 34904043 DOI: 10.4254/wjh.v13.i11.1753] [Reference Citation Analysis]
111 Zhang Y, Li Y, Jiang W, Li Q, Lan Y. The clinical significance of microRNA-122 in predicting the prognosis of patients with hepatocellular carcinoma: A meta-analysis validated by the Cancer Genome Atlas dataset. Medicine (Baltimore) 2019;98:e14810. [PMID: 30921182 DOI: 10.1097/MD.0000000000014810] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 3.3] [Reference Citation Analysis]
112 Banini BA, Sanyal AJ. The use of cell free DNA in the diagnosis of HCC. Hepatoma Res 2019;5:34. [PMID: 31673629 DOI: 10.20517/2394-5079.2019.30] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
113 He S, Zhang DC, Wei C. MicroRNAs as biomarkers for hepatocellular carcinoma diagnosis and prognosis. Clin Res Hepatol Gastroenterol. 2015;39:426-434. [PMID: 25746139 DOI: 10.1016/j.clinre.2015.01.006] [Cited by in Crossref: 30] [Cited by in F6Publishing: 30] [Article Influence: 4.3] [Reference Citation Analysis]
114 Gorczynski RM, Zhu F, Chen Z, Kos O, Khatri I. A comparison of serum miRNAs influencing metastatic growth of EMT6 vs 4THM tumor cells in wild-type and CD200R1KO mice. Breast Cancer Res Treat 2017;162:255-66. [DOI: 10.1007/s10549-017-4128-5] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
115 Kim SS, Nam JS, Cho HJ, Won JH, Kim JW, Ji JH, Yang MJ, Park JH, Noh CK, Shin SJ, Lee KM, Cho SW, Cheong JY. Plasma micoRNA-122 as a predictive marker for treatment response following transarterial chemoembolization in patients with hepatocellular carcinoma. J Gastroenterol Hepatol 2017;32:199-207. [PMID: 27194671 DOI: 10.1111/jgh.13448] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 2.6] [Reference Citation Analysis]